Bioequivalence Study
NCT01874080 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2015-04-23
Summary
The purpose of this study is to determine if tablets manufactured at different sites have the same bioavailability, that is yield similar blood levels/concentrations of the drugs and are handled by the body similarly
Conditions
Interventions
- DRUG
-
Saxagliptin/Metformin
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2013-07-31
- Completion
- 2013-07-31
Countries
- United States
Study Locations
More Related Trials
-
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
NCT01068717 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
NCT01365091 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc
NCT01441869 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
NCT01068743 ·Status: COMPLETED ·Phase: PHASE1
-
BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
NCT01305551 ·Status: WITHDRAWN ·Phase: PHASE1
-
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
NCT03138356 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
NCT05549583 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
NCT06233240 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
NCT00961480 ·Status: COMPLETED ·Phase: PHASE1
-
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
NCT03216278 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
NCT02637037 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
NCT06233201 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers
NCT05549570 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
NCT01093794 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
NCT00929201 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)
NCT00961857 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
NCT01068730 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
NCT00798161 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
NCT00740051 ·Status: COMPLETED ·Phase: PHASE3
-
A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
NCT03776227 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
NCT01011868 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
NCT00944450 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
NCT01055691 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
NCT06124560 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.
NCT02084056 ·Status: COMPLETED ·Phase: PHASE1